HCG 5000IU/amp 1 Ampulle by Nassa Labs

Usage

1. Reconstitute the ampoule: Draw 1–2 ml of bacteriostatic water for injection (or sterile water for injection) into a clean syringe and inject gently into the HCG powder ampoule; swirl — do not shake — until fully dissolved.
2. Calculate your mini-PCT portion: For a mild-cycle protocol targeting 500–1000 IU per injection, divide the reconstituted volume accordingly (e.g., 1 ml total volume with 5000 IU = 0.1–0.2 ml per 500–1000 IU dose).
3. Timing relative to your last compound dose: Administer the first injection within 48–72 hours of taking your final mild-cycle anabolic compound — earlier initiation is appropriate when using shorter-ester compounds.
4. Injection technique: Using a fresh needle (25–27 G, 5/8–1 inch), inject subcutaneously into the lower abdomen or intramuscularly into the ventrogluteal site, rotating sites between injections.
5. Storage between doses: Refrigerate any remaining reconstituted solution at 2–8 °C; use within 30 days. Label the ampoule or vial with reconstitution date and maintain aseptic handling on every draw.
6. Transition to SERM: After your final HCG injection (typically after 7–10 days for a mild cycle), wait 3–4 days before starting your chosen SERM at a conservative dose to complete hormonal recovery.

Warnings

Frequently asked questions

Do you actually need HCG after a mild anabolic cycle, or can you skip it?

Whether HCG is necessary depends on the degree of suppression. A mild cycle — short duration, single compound, moderate dose — often produces only partial suppression, so many practitioners opt for a brief HCG phase rather than skipping recovery altogether. Skipping any PCT risks a prolonged low-testosterone window even after mild suppression; a short 1–2 week hCG course bridges that gap efficiently and reduces recovery time before SERM consolidation.

How short can a mini-PCT with HCG realistically be after a low-suppression cycle?

A mini-PCT for mild suppression typically spans 7–14 days of HCG use, compared to the 3–4 week gonadotropin phases associated with heavy-cycle recovery. Given that mild cycles leave Leydig cell sensitivity relatively intact, a condensed schedule of 2–3 injections totalling 1500–2000 IU is often sufficient to restore endogenous testosterone signalling before transitioning to a short SERM phase.

Which SERM pairs best with HCG in a mild-cycle mini-PCT?

Clomiphene citrate or tamoxifen citrate at conservative doses — 25 mg clomiphene or 10–20 mg tamoxifen daily for 2–3 weeks — are the standard SERM choices following mild-cycle HCG use. Because the suppression baseline is lower, full-dose SERM protocols are rarely warranted; a reduced-dose SERM run started 3–4 days after the final HCG injection typically achieves satisfactory LH restoration without side-effect burden.

Does the single-ampoule format of Nassa Labs HCG 5000IU present sterility concerns when splitting doses for a mini-PCT?

Single-dose ampoules are sealed under aseptic conditions and remain sterile until opened; once breached, the solution should be used within 24–48 hours if refrigerated at 2–8 °C, or ideally within one session. For a mini-PCT requiring multiple small injections, practitioners often reconstitute the full 5000 IU, draw the planned portion immediately, and store the remainder under refrigeration in a capped syringe or vial — always following aseptic technique to preserve sterility between draws.

What is the correct storage condition for Nassa Labs HCG 5000IU/amp before and after reconstitution?

Unreconstituted Nassa Labs HCG ampoules should be stored at 2–8 °C away from direct light; do not freeze. After reconstitution with the supplied bacteriostatic water or sterile water for injection, the solution remains stable for up to 30 days when refrigerated at 2–8 °C, provided aseptic technique was used during preparation. Discard any solution showing particulate matter, discolouration, or that has been stored beyond the reconstitution stability window. (2) angle_used

Manufacturer

Nassa Labs' product portfolio spans the major compound categories used across anabolic and recovery cycles — injectable gonadotropins including this HCG 5000IU/amp, injectable androgen esters, oral androgens, aromatase inhibitors, and selective estrogen receptor modulators — structured so that each category is supported by a dedicated quality control pathway rather than a single blanket process. For the HCG ampoule line specifically, the quality dimension Nassa Labs anchors transparency to is finished-product batch testing: every HCG lot must clear two independent analytical gates — an HPLC content quantification confirming the declared 5000 IU potency against a certified reference standard, and an LAL endotoxin screen verifying pyrogen-free sterility — before a distribution lot code is assigned and the product enters the supply chain. This portfolio-wide commitment to per-category, batch-level testing means that whether a practitioner is sourcing a gonadotropin for mini-PCT use or an oral SERM for SERM consolidation, each Nassa Labs product carries its own independently verified release record rather than relying on a shared manufacturing clearance.